Kadcyla for lung cancer – pro
HER-2targeted drugs, such as trastuzumab (Herceptin), may be useful in a small percentage of cases of lung cancer. Mazieres et al found response rates in STUDY OF 16 PATIENTS. In 2017 LI published a study of K ADCYLA that found some effectiveness. Ado-trastuzumab emtansine is active and well tolerated in pts with HER2 mutant lung cancers. This study has met its primary endpoint. The authors say that further development in a multicenter study is warranted.As such, more information is needed and Kadcyla is still experimental for lung cancer.
Julien Mazières et al, Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. ournal of Clinical Oncology 31, no. 16 (June 2013) 1997-2003.
Bob T. Li, Ronglai Shen, Darren Buonocore, Zachary T. Olah, Ai Ni, Michelle S. Ginsberg, Gary Ulaner, Wolfgang Weber, Marc Ladanyi, Helen H. Won, Gregory J. Riely, David B. Solit, David Michael Hyman, Charles M. Rudin, Michael F. Berger, Maurizio Scaltriti, Jose Baselga, Mark G. Kris, Maria E. Arcila; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY, Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.. J Clin Oncol 35, 2017 (suppl; abstr 8510)